Abstract 1498P
Background
Acute myeloid leukemia (AML) is a fatal cancer in patients over 65 years old, with a five-year relative survival rate of 10.8%. There is no literature regarding specific determinants of palliative care (PC) utilization in this population. We studied trends and determinants in PC utilization among hospitalized patients using the National Inpatient Sample (NIS).
Methods
This is a retrospective study using NIS data from 2016 to 2020. We included patients aged 65 years or older who were admitted with AML. We identified patients who had an encounter with PC during their hospitalization. The cohort was divided between patients with an encounter with PC and those without. Baseline characteristics were identified and compared between the two groups. Total charges (TC) during hospitalization were measured as an outcome, and then multivariate logistic regression analysis was performed to adjust for confounders.
Results
There were 44,375 patients over 65 years old admitted with AML. Of those, 22% had an encounter with PC. Baseline characteristics and differences between those in which PC was consulted and those in which they were not consulted are depicted in the table. Significant differences were observed in patients who had an encounter with PC, such as higher utilization in the White race (78% vs. 75%). They had higher rates of Heart Failure (HF) (23% vs 17%, p<0.001), acute kidney injury (AKI) (44% vs. 30%, p<0.001), and chronic kidney disease (CKD) (15% vs 12%, p 0.0018) than patients who did not have an encounter with PC. Type of insurance and hospital bed size were not significantly associated with PC utilization. Significantly, PC was consulted less in hospitals in the south region. While adjusting for other confounders, in the multivariate regression analysis, encounters with PC were associated with a decrease in TC during hospitalization of $ 49,047 (p<0.001).
Conclusions
Overall, PC utilization was low. It was reduced in hospitals located in the south region of the USA. It was higher in patients of the White Race and in patients with HF, AKI, and CKD and was associated with decreased cost burden. Our results highlight the need for early palliative care involvement in patients with AML in hospital settings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1564P - Limited participation in breast cancer screening among low-SES women: A matter of engagement or of health literacy?
Presenter: Allegra Ferrari
Session: Poster session 10
1566P - Optimizing participation in lung cancer screening program: Results from the first round in ILYAD study in Lyon University Hospital
Presenter: Emmanuel Grolleau
Session: Poster session 10
1567P - Physicians' adenoma detection rate and the risk of colorectal cancer in sequential screening programs: An observational cohort study
Presenter: Li Xie
Session: Poster session 10
1568P - Challenges in pilot lung cancer screening in Vojvodina, Serbia
Presenter: Jelena Djekic Malbasa
Session: Poster session 10
1569P - Secondary delay in breast cancer diagnosis and role of rural medical practitioners: A cause and cure finding study
Presenter: Rahul Agarwal
Session: Poster session 10
1570P - Factors and impacts of delayed presentation for county-level patients with breast cancer in a real-life setting in China
Presenter: Yinghua Ji
Session: Poster session 10
1571P - The reasons that motivate a change of specialties among oncology residents
Presenter: Christophe Ducrocq
Session: Poster session 10
1572P - Factors associated with career choice in oncology among medical students
Presenter: Nicolas Penel
Session: Poster session 10
1573P - Global cancer statistics for adolescents and young adults: New estimates from GLOBOCAN 2022
Presenter: Wang-Zhong Li
Session: Poster session 10
Resources:
Abstract